Health Canada has authorized Eli Lilly's new oral GLP‑1 medication for weight loss, to be taken daily, effective November 18, 2026.
The approval introduces the first daily pill form of a GLP‑1 drug in Canada, expanding treatment options beyond the weekly injections that have previously been the only delivery method for this class of weight‑loss medicines.
